UA5778U - Способ лечения опийной наркомании по хиллеру-сердюку - Google Patents
Способ лечения опийной наркомании по хиллеру-сердюку Download PDFInfo
- Publication number
- UA5778U UA5778U UA20040806980U UA2004806980U UA5778U UA 5778 U UA5778 U UA 5778U UA 20040806980 U UA20040806980 U UA 20040806980U UA 2004806980 U UA2004806980 U UA 2004806980U UA 5778 U UA5778 U UA 5778U
- Authority
- UA
- Ukraine
- Prior art keywords
- dose
- catapressan
- dormicum
- patient
- body weight
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 21
- 206010013663 drug dependence Diseases 0.000 title claims abstract description 8
- 208000004224 Opium Dependence Diseases 0.000 title claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 14
- XYGVIBXOJOOCFR-BTJKTKAUSA-N (z)-but-2-enedioic acid;8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo[1,5-a][1,4]benzodiazepine Chemical compound OC(=O)\C=C/C(O)=O.C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F XYGVIBXOJOOCFR-BTJKTKAUSA-N 0.000 claims abstract description 13
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims abstract description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 12
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960004134 propofol Drugs 0.000 claims abstract description 10
- 230000037396 body weight Effects 0.000 claims abstract description 9
- 238000001784 detoxification Methods 0.000 claims abstract description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 6
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 6
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 6
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 6
- 239000011718 vitamin C Substances 0.000 claims abstract description 6
- 229940072018 zofran Drugs 0.000 claims abstract description 6
- 229940095970 imodium Drugs 0.000 claims abstract 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 11
- 229960004127 naloxone Drugs 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 9
- 238000002695 general anesthesia Methods 0.000 claims description 8
- 238000001990 intravenous administration Methods 0.000 claims description 8
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 6
- 108010016076 Octreotide Proteins 0.000 claims description 6
- 229960003086 naltrexone Drugs 0.000 claims description 6
- 229940072272 sandostatin Drugs 0.000 claims description 6
- 238000009101 premedication Methods 0.000 abstract description 7
- 210000002784 stomach Anatomy 0.000 abstract description 4
- 238000003556 assay Methods 0.000 abstract 1
- 239000002869 intravenous anesthetic agent Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 8
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 5
- 208000026251 Opioid-Related disease Diseases 0.000 description 4
- 201000005040 opiate dependence Diseases 0.000 description 4
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 3
- 206010048010 Withdrawal syndrome Diseases 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 229960001797 methadone Drugs 0.000 description 3
- 229940127240 opiate Drugs 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
- 102000003840 Opioid Receptors Human genes 0.000 description 2
- 108090000137 Opioid Receptors Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960002069 diamorphine Drugs 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 2
- 229960001596 famotidine Drugs 0.000 description 2
- 238000002690 local anesthesia Methods 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 210000001260 vocal cord Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 101100325762 Amanita phalloides AMA2 gene Proteins 0.000 description 1
- 208000003698 Heroin Dependence Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- -1 angioprotectors Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Способ лечения опийной наркомании включает в себя поэтапное медикаментозное воздействие. Проводят премедикацию, вводя внутримышечно на протяжении 4 часов раствор катапрессана в дозе 50-150 мкг/кг веса тела, дормикум в дозе 2,5-10 мг/кг веса тела, витамин С 1-2 г и одну таблетку имодиума. Проводят общую анестезию внутривенным введением пропофола в дозе 100-200 мг и дормикума в дозе 10-15 мг. Проводят детоксикацию организма, вводя на протяжении 4 часов ежечасно внутривенно фамотедин в дозе 0,3-10 мг/кг в сочетании с зофраном в дозе 0,05-5 мг/кг, а внутрижелудочно - нальтрексон в дозе 0,05-1,5 мг/кг в сочетании с катапрессаном в дозе 0,1-5 мг/кг, одновременно три раза подкожно вводят раствор пептида. После последнего дозирования лекарств проводят налоксоновую пробу.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA20040806980U UA5778U (ru) | 2004-08-21 | 2004-08-21 | Способ лечения опийной наркомании по хиллеру-сердюку |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA20040806980U UA5778U (ru) | 2004-08-21 | 2004-08-21 | Способ лечения опийной наркомании по хиллеру-сердюку |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA5778U true UA5778U (ru) | 2005-03-15 |
Family
ID=74494551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20040806980U UA5778U (ru) | 2004-08-21 | 2004-08-21 | Способ лечения опийной наркомании по хиллеру-сердюку |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA5778U (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2646569C2 (ru) * | 2016-07-05 | 2018-03-05 | Федеральное государственное бюджетное учреждение "Новосибирский научно-исследовательский институт травматологии и ортопедии им. Я.Л. Цивьяна" Министерства здравоохранения Российской Федерации (ФГБУ "ННИИТО им. Я.Л. Цивьяна" Минздрава России) | Способ лечения метадоновой зависимости |
-
2004
- 2004-08-21 UA UA20040806980U patent/UA5778U/ru unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2646569C2 (ru) * | 2016-07-05 | 2018-03-05 | Федеральное государственное бюджетное учреждение "Новосибирский научно-исследовательский институт травматологии и ортопедии им. Я.Л. Цивьяна" Министерства здравоохранения Российской Федерации (ФГБУ "ННИИТО им. Я.Л. Цивьяна" Минздрава России) | Способ лечения метадоновой зависимости |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2519660C2 (ru) | Режим дозировки селективного агониста рецептора s1p1 | |
| EP0200490B1 (en) | Compositions for noninvasive administration of sedatives, analgesics, and anesthetics | |
| US8912211B2 (en) | Medicinal compositions comprising buprenorphine and naltrexone | |
| US20070203247A1 (en) | Epinephrine dosing regimens | |
| AU2008220574A1 (en) | Improvements in and relating to medicinal compositions | |
| CN1592616A (zh) | 与神经甾体活性降低相关的疾病的治疗中的gaba增强剂 | |
| Harris et al. | β-adrenergic antagonism alters the behavioral and neurochemical responses to cocaine | |
| KR101437461B1 (ko) | 부프레노르핀 및 날메펜을 함유하는 개량 약용 조성물 | |
| US20200000843A1 (en) | Composition for improvement or prevention of parkinsonian syndrome | |
| EP0236477B1 (en) | Use of 6-methylene-6-desoxy-n-cyclopropylmethyl-14-hydroxydihydronormorphine | |
| RU2322985C2 (ru) | Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости | |
| RU2310449C1 (ru) | Способ лечения опиоидной и/или алкогольной зависимости | |
| Brown et al. | Withdrawal from long-term high-dose desipramine therapy: clinical and biological changes | |
| UA5778U (ru) | Способ лечения опийной наркомании по хиллеру-сердюку | |
| Shin et al. | Risk factor analysis of additional administration of sedative agent and patient dissatisfaction in intravenous conscious sedation using midazolam for third molar extraction | |
| RU2646569C2 (ru) | Способ лечения метадоновой зависимости | |
| CN1346278A (zh) | 麻醉的调节 | |
| RU2022572C1 (ru) | Способ лечения туберкулеза легких | |
| RU2556792C1 (ru) | Способ анестезии при выполнении операции циклофотокоагуляция у пациентов с синдромом "хронической" боли | |
| RU2227031C2 (ru) | Способ лечения наркомании | |
| RU2282453C2 (ru) | Способ терапии больных сахарным диабетом ii типа | |
| RU2479323C1 (ru) | Способ предоперационной подготовки больных с хроническим панкреатитом и выраженным болевым синдромом | |
| WO2022175973A1 (en) | An injectable composition for long term delivery of nalbuphine or nalbuphine ester prodrug or its salts and use thereof | |
| UA63997C2 (ru) | Лекарственное средство для лечения пациентов с опийной зависимостью и способ лечения | |
| AU2012289763B2 (en) | Intrathecal or epidural administration of 3-[(1S,2S)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol |